Q1 FY27 growth quarter expected
Management does not see a degrowth quarter in Q1 FY27, though geopolitical uncertainty makes prediction difficult.
ZENSARTECHNOLOGIES / guidance tracker
Keep management guidance in view.
Zensar Technologies · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
Mid-teens EBITDA margin for FY27
CFO reiterated mid-teens margin guidance for FY27, with possible quarterly variations due to large deal transition costs.
Large deal ramp-up: full revenue from Q3 FY27
Mega deal revenue will start in Q1, but full-fledged revenue expected from Q3 FY27; transition costs will pressure margins in H1.
Healthcare & Life Sciences flat in FY27
After 8.6% growth in FY26, management expects HLS revenue to remain at least flat in FY27 due to account consolidation.